Arrowstreet Capital’s BioNTech BNTX Stock Holding History

Arrowstreet Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.63M	Buy	28,293 +22,677	+404%	+$2.13M	﹤0.01%	1463
2026 Q1	$499K	Buy	+5,616	New	+$577K	﹤0.01%	1672
2025 Q1	–	Sell	-30,827	Closed	-$3.51M	–	1817
2024 Q4	$3.51M	Buy	+30,827	New	+$3.52M	﹤0.01%	1114
2023 Q2	–	Sell	-104,491	Closed	-$13M	–	1228
2023 Q1	$13M	Sell	104,491 -67,358	-39%	-$9.25M	0.02%	498
2022 Q4	$25.8M	Buy	+171,849	New	+$26.4M	0.04%	335
2022 Q1	–	Sell	-5,609	Closed	-$1.45M	–	1208
2021 Q4	$1.45M	Sell	5,609 -40,165	-88%	-$11M	﹤0.01%	1084
2021 Q3	$12.5M	Buy	+45,774	New	+$14.5M	0.02%	661

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Arrowstreet Capital's BNTX Position: Q2 2026 in Review

Arrowstreet Capital increased its BioNTech (BNTX) stake by 404% in Q2 2026, buying an estimated $2.13M and bringing the position to 28,293 shares worth $2.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1463.

Arrowstreet Capital first reported a position in BNTX in Q3 2021 and has held it in 7 quarters since. The position peaked at $25.8M in Q4 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Arrowstreet Capital held 28,293 shares of BioNTech worth $2.63M as of Q2 2026.
Arrowstreet Capital bought 22,677 BioNTech shares in Q2 2026, an estimated $2.13M.
BioNTech made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1463 holding.
Arrowstreet Capital first reported a position in BioNTech in Q3 2021 and has held it in 7 quarters since.
Arrowstreet Capital's BioNTech position peaked at $25.8M in Q4 2022.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.